Don’t invest unless you’re prepared to lose all your money. These are high-risk investments and you are unlikely to be protected if something goes wrong.
Take 2 mins to learn more

Family Office

We provide access to investment in emerging science from start-ups to IPO’s.

Working with your family office to understand

your investment requirements in the medtech and biotech sectors.

Norcliffe Capital works with your family office to provide investment opportunities in the MedTech and BioTech sectors. Our investments are a key aspect of your overall portfolio, providing access to companies with groundbreaking technology, strong IP and the potential for exponential growth, in sectors that are uncorrelated to the markets.

We use our experience of founding and managing MedTech companies to identify emerging technology with the potential to transform lives. Tomorrow’s great companies will be based on the breakthrough research we see today.

We have an active programme of engagement with universities, academics and start-up companies to identify key trends in medicine and biotechnology. Early engagement provides access to new advances in technology at an early stage, enabling Norcliffe Capital to select specific categories you are interested in or to diversify your investment portfolio.

Depending on the level of investment, family offices can take a seat on the board, or you can rely on Norcliffe Capital to represent you and protect your interests.

You will receive regular and open communications throughout.

Risk Warning

Your capital will be at risk and there is no guarantee of any investment return. The value of investments may go down and you could lose all of your investment. Private company investments are not listed on any market and this means that you may not be able to sell them when you want to do so. This sort of investment does not provide a reliable source of income. The tax benefits of private company investing depend on your personal circumstances and on compliance with the relevant rules. Past performance is not a reliable indicator of future results. We do not provide investment, tax or legal advice.